Skip to content

Effects of Platelet-rich Plasma Prolotherapy of Temporomandibular Joint Subluxation

The Effects of Platelet-rich Plasma Prolotherapy on Pain Score and Frequency of Luxation in Temporomandibular Joint Subluxation A Prospective Randomized Placebo Controlled Trial

Status
UNKNOWN
Phases
Early Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03655275
Enrollment
22
Registered
2018-08-31
Start date
2018-08-24
Completion date
2019-05-30
Last updated
2018-09-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Temporomandibular Joint Disorders

Keywords

subluxation , platelet rich plasma (PRP), prolotherapy.

Brief summary

The aim of this study is to clinically assess the efficacy of PRP prolotherapy for treatment of TMJ subluxation

Detailed description

The effect of platelet-rich plasma prolotherapy on the pain score and frequency of luxation in temporomandibular joint subluxation. A prospective randomized placebo controlled trial * After detailed clinical evaluation, every patient will undergo routine preoperative laboratory tests (complete blood cell count, HCV , HBV , Tomogram of TMJ examination). In cases in which special diagnostic procedures will be needed for more detailed evaluation of the patients, they will also be performed. * All cases will undergo to withdraw 40 ml of blood from the patient's upper limb cubital vein using an 18G needle, subsequently 5 ml of citrate sodium solution is added to the sample as an anticoagulant. One milliliter of the blood sample will be sent for complete blood count. * To prepare of high concentration PRP the blood sample will be then centrifuged for 15 minutes at 1600 rpm resulting in three layers: the lower layer made up of red blood cells, the intermediate layer is composed of white blood cells, and the upper layer is composed of plasma. The Buffy coat layer and the plasma layer will be later collected and centrifuged for another 7 minutes at 2800 rpm in order to concentrate platelets. The final product will be about 4-6 mL of PRP containing leukocytes. * the skin surface of the preauricular area will be disinfected with Betadine surgical scrub solution. The anatomic landmarks will be located by asking the patient to open widely to allow drawing of the articular fossa and then to close lightly on the posterior teeth to draw the condyle within the glenoid fossa. * Typically, each joint had 3 injection sites: * The needle will be inserted at lateral margin of the glenoid fossa and 0.5 ml of the PRP will be slowly injected at the superior capsular attachment .Then needle will be directed immediately under the lateral margin of the glenoid fossa superiorly and medially toward the apex of the fossa.1ml of the PRP will be then slowly injected into the superior joint space * The needle will be inserted at the condylar neck and 0.5 ml of the PRP will be injected at the inferior capsular attachment. Then needle will be directed superficial to the TMJ capsule, 0.5 ml of the PRP will be deposited as needle will be withdrawn. * patients in the placebo group received injections of placebo (saline) using the same volume on the same schedule. * Post operative care and instructions: * Bleeding from the injection sites will be generally minimal and could be controlled with direct pressure on the injection site for a few seconds. * All patients will be advised to take paracetamol, one tablet when needed and to stop the use of other pain and anti-inflammatory drugs during the treatment phase. * Each patient will be instructed to receive soft diet only for two weeks in order to decrease the effort upon TMJ .

Interventions

BIOLOGICALPRP prolotherapy

PRP prolotherapy By injection 2.5ml of PRP at an interval of 2 weeks.

Saline prolotherapy Injection 2.5 ml of saline at an interval of 2 weeks.

Sponsors

Cairo University
CollaboratorOTHER
Abdelrahman Soliman Alateyh
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Masking description

This study is randomized, placebo controlled trial.

Intervention model description

This study is randomized, placebo controlled trial.

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Patients who had TMJ subluxation for at least six months. 2. Age ≥ 18 years 3. Willingness of the patient to receive relative painful injections and to follow instructions.

Exclusion criteria

* 1\. Patients with dystonia 2. Drug induced TMJ hypermobility 3. Medical conditions that could significantly interfere with treatment

Design outcomes

Primary

MeasureTime frameDescription
Patients' subjective pain experienceup to 40 weeksvisual anlogue scale (VAS) from 0 - 10

Secondary

MeasureTime frameDescription
Frequency of luxationup to 40 weeksThe number of luxation/day
Maximum mouth openingup to 40 weeksruler per mm from 0 - 70
Joint soundsup to 40 weekspreauricular palpation

Countries

Egypt

Contacts

Primary Contactabdelrahman alatyeh, B.D.S
abo.noorsyria@gmail.com00201099179039

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026